Floatz logo

XENON

Bronchopulmonary Dysplasia

Thunder Bay Regional Health Research InstituteSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Bronchopulmonary Dysplasia cohort.

Asset / SponsorPhaseRating
Dexasone
National Center for Research Resources (NCRR)
Phase 3B
Hydrocortisone
National Center for Research Resources (NCRR)
Phase 2B
Helium
Thunder Bay Regional Health Research Institute
Early Phase 1C
Sulfur Hexafluoride
Thunder Bay Regional Health Research Institute
Early Phase 1C
Perflutren
Thunder Bay Regional Health Research Institute
Early Phase 1C
Cord Blood Red Blood Cells
Hospital Clinic of Barcelona
N/AD
Red Blood Cells
Hospital Clinic of Barcelona
N/AD

Same molecule, other indications

XENON is also rated in:

cystic fibrosisActive
BB
Indicative · Phase 4
65 / 100
View asset →
asthmaActive
B
Indicative · Phase 2
63 / 100
View asset →
pulmonary fibrosisActive
B
Indicative · Phase 2
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →